BICO Group AB Class B (CLLKF)
OTHER OTC:CLLKF
CLLKF Stock Chart & Stats
$1.98
$0.10(3.47%)
At close: 4:00 PM EST
$1.98
$0.10(3.47%)
Day’s Range― - ―
52-Week Range$1.60 - $4.14
Previous CloseN/A
Volume500.00
Average Volume (3M)167.00
Market Cap
$133.31M
Enterprise Value$1.23B
Total Cash (Recent Filing)$744.30M
Total Debt (Recent Filing)$690.60M
Price to Earnings (P/E)―
Beta0.52
Next Earnings
Aug 19, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-13.97
Shares Outstanding69,074,900
10 Day Avg. Volume250
30 Day Avg. Volume167
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.85
Price to Sales (P/S)0.99
P/FCF Ratio26.97
Enterprise Value/Market Cap9.23
Enterprise Value/Revenue0.82
Enterprise Value/Gross Profit1.83
Enterprise Value/Ebitda-1.16
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.25
Revenue Forecast (FY)$168.32M
Bulls Say, Bears Say
Bulls Say
Recurring Revenue ModelBICO’s business drives recurring consumables, software licenses and service revenues from installed instruments. That installed-base driven model creates durable revenue visibility and higher lifetime customer value, supporting cash flow stability if instrument placements recover.
Diversified Product PortfolioA multi‑business portfolio across bioprinting, automation, consumables and software reduces single‑product risk and enables cross‑selling to academic and biopharma customers. This structural diversification supports resilience and incremental revenue channels over the medium term.
Improving Gross Margins & Positive Cash FlowMargin improvement and currently positive operating cash flow indicate better underlying unit economics and near‑term cash generation. If sustained, higher gross margins improve the path to profitability and provide runway to fund growth or reduce leverage over the next several quarters.
Bears Say
Large Recurring LossesA ~-70% net margin denotes persistent deep losses that erode shareholder value and limit reinvestment. Continued operating losses constrain the company’s ability to self‑fund R&D and commercial expansion, increasing reliance on external financing and raising dilution or covenant risk.
Revenue ContractionDeclining revenue weakens the recurring revenue base and slows installed‑base growth, undermining consumables and service follow‑on sales. Sluggish top‑line trends make margin recovery and sustainable cash generation harder over a multi‑quarter horizon.
Volatile Cash Generation And Eroded EquitySharp FCF deterioration and a shrinking equity base signal cash‑flow volatility and reduced balance‑sheet capacity to absorb shocks. That elevates refinancing risk and limits strategic optionality for capex, M&A or sustained commercial investment without external capital.
BICO Group AB Class B News
CLLKF FAQ
What was BICO Group AB Class B’s price range in the past 12 months?
BICO Group AB Class B lowest stock price was $1.60 and its highest was $4.14 in the past 12 months.
What is BICO Group AB Class B’s market cap?
BICO Group AB Class B’s market cap is $133.31M.
When is BICO Group AB Class B’s upcoming earnings report date?
BICO Group AB Class B’s upcoming earnings report date is Aug 19, 2026 which is in 74 days.
How were BICO Group AB Class B’s earnings last quarter?
BICO Group AB Class B released its earnings results on Apr 29, 2026. The company reported -$0.183 earnings per share for the quarter, missing the consensus estimate of -$0.106 by -$0.077.
Is BICO Group AB Class B overvalued?
According to Wall Street analysts BICO Group AB Class B’s price is currently Overvalued.
Does BICO Group AB Class B pay dividends?
BICO Group AB Class B does not currently pay dividends.
What is BICO Group AB Class B’s EPS estimate?
BICO Group AB Class B’s EPS estimate is -0.08.
How many shares outstanding does BICO Group AB Class B have?
BICO Group AB Class B has 69,074,900 shares outstanding.
What happened to BICO Group AB Class B’s price movement after its last earnings report?
BICO Group AB Class B reported an EPS of -$0.183 in its last earnings report, missing expectations of -$0.106. Following the earnings report the stock price went up 10.243%.
Which hedge fund is a major shareholder of BICO Group AB Class B?
Currently, no hedge funds are holding shares in CLLKF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BICO Group AB Class B
BICO Group AB (publ) operates as a bio convergence company in North America, Europe, Asia, and internationally. It operates through two segments, Laboratory Solutions and Bioautomation. The Laboratory Solutions segment offers 3D bioprinters, hybrid microscopes, single-cell dispensing instruments, and liquid handling instruments, as well as services and related consumables, such as bioinks, reagents, microscope lenses, software, printheads, and 3D reconstructed human tissues for applications in regulatory testing. This segment also offers services in 3D cell culture, 3D tissue imaging, multiplex imaging, and digital pathology to pharmaceutical and biotechnology companies. The Bioautomation segment offers products in precision dispensing and biosensor technology to the industrial customer; and diagnostics automation and advanced robotics solutions for the medical and diagnostic industries. In addition, it offers core industrial ecosystem, tissue engineering, multi-omics, cell line development, and diagnostics solutions. It primarily serves medical, pharmaceutical, and cosmetic industries. The company was formerly known as Cellink AB (publ) and changed its name to BICO Group AB (publ) in August 2021. BICO Group AB (publ) was founded in 2016 and is based in Gothenburg, Sweden.
CLLKF Company Deck
CLLKF Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a balanced picture: the company executed its strategic repositioning (BICO 2.0), strengthened its cash position through a EUR 40m bond issuance, reduced debt and demonstrated a clear Q4 recovery with strong margins and Biosero momentum. However, full-year financials were weak (organic sales -8%, adjusted EBITDA only SEK 5m, Lab Automation full-year decline -26% and negative EBITDA), and the business faced notable macro headwinds (US academia funding cuts, FX pressure and cautious CapEx). Product launches, partnerships and AI-enabled offerings provide a foundation for growth, but near-term performance still reflects industry and legacy operational challenges.View all CLLKF earnings summariesTechnical Analysis
CellaVision AB
―
Senzime AB
―
Bactiguard Holding AB
―
C-Rad AB Class B
―
Sedana Medical AB
―
Ownership Overview
―
Insiders
0.02% Mutual Funds
1.56% Other Institutional Investors
96.23% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---